SCHEMBL12092017

SCHEMBL12092017

CCC#Cc1ccccc1O[C@@H](C)CO

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
MCHR1 Q99705 3/20 0.33
PTGS2 P35354 1/20 0.32
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
AGTR1 P30556 1/20 0.31
LMNA P02545 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
HTR1A P08908 1/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30
MAOA P21397 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12092014 1.00 CYP1A2 (0.33) CYP1A2KDM4EMTNR1AMTNR1BALDH1A1
SCHEMBL12092011 1.00 CYP1A2 (0.33) CYP1A2KDM4EMTNR1AMTNR1BALDH1A1
SCHEMBL12092010 0.87 MCHR1 (0.43) MTNR1AMTNR1BALDH1A1MCHR1LMNA
SCHEMBL12092012 0.87 MCHR1 (0.43) MTNR1AMTNR1BALDH1A1MCHR1LMNA
SCHEMBL12092013 0.87 MCHR1 (0.43) MTNR1AMTNR1BALDH1A1MCHR1LMNA
SCHEMBL13696905 0.86 CYP1A2 (0.37) CYP1A2KDM4EMTNR1AMTNR1BALDH1A1
SCHEMBL14942933 0.83 MCHR1 (0.45) KDM4EMTNR1AMTNR1BALDH1A1MAPT
SCHEMBL12134876 0.82 PTGDR2 (0.34) CYP1A2CYP3A4CYP2C9CYP2C19PTGDR2
SCHEMBL12634564 0.82 MCHR1 (0.34) KDM4EMTNR1AMTNR1BMCHR1MAPK1
SCHEMBL14092175 0.80 CYP2D6 (0.39) CYP1A2KDM4EALDH1A1SMN1; SMN2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120226067-A1 PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS MARSAULT ERIC (CA) 2012-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120226067-A1 PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS MLNR, CHRM2, CCKAR CYP1A2 942/4885KDM4E 4753/4885MTNR1A 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.